Cargando…
Safety evaluation of shorter infusion for ocrelizumab in a substudy of the Phase IIIb CHORDS trial
The CHORDS trial evaluated ocrelizumab (OCR) in patients with relapsing‐remitting multiple sclerosis who had a suboptimal response to previous disease‐modifying treatment. The objective of the present study was to assess the safety of shorter OCR infusions in a substudy of CHORDS. After completing f...
Autores principales: | Bermel, Robert A., Waubant, Emmanuelle, Pardo, Gabriel, Bass, Ann, Repovic, Pavle, Newsome, Scott, Lindsey, John W., Kile, Deidre, Pradhan, Ashish, Musch, Bruno, Zabeti, Aram |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7951110/ https://www.ncbi.nlm.nih.gov/pubmed/33621404 http://dx.doi.org/10.1002/acn3.51310 |
Ejemplares similares
-
Ocrelizumab shorter infusion: Primary results from the ENSEMBLE PLUS substudy in patients with MS
por: Hartung, Hans-Peter
Publicado: (2020) -
Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis
por: Hartung, H-P, et al.
Publicado: (2020) -
Ocrelizumab treatment for relapsing-remitting multiple sclerosis
after a suboptimal response to previous disease-modifying therapy: A
nonrandomized controlled trial
por: Weinstock-Guttman, Bianca, et al.
Publicado: (2021) -
Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients
por: Akgün, Katja, et al.
Publicado: (2022) -
Safety and patient experience with at‐home infusion of ocrelizumab for multiple sclerosis
por: Barrera, Britney, et al.
Publicado: (2023)